FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655443> ?p ?o ?g. }

• W4385655443 endingPage "e8253025" @default.
• W4385655443 startingPage "e8253025" @default.
• W4385655443 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Even though proton pump inhibitors (PPIs) significantly decrease the risk of gastrointestinal (GI) bleedings in the general population, these medications also have a pharmacodynamic interaction with aspirin and clopidogrel, potentially decreasing their antiplatelet effect. Patients with essential thrombocythemia (ET) and polycythemia vera (PV) often suffer from peptic ulcer disease and frequently receive low-dose aspirin (75-100 mg) due to intrinsically high thrombotic risk. Aims: To investigate whether PPIs may have an effect on thrombohemorrhagic risk in low-dose aspirin-treated ET and PV patients. Methods: This was a multicenter study conducted at three community hospitals in Croatia. Patients with ET and PV whose disease diagnosis was reassessed according to 2016 World Health Organization criteria were retrospectively included in the period between 2001 and 2022. Clinical and laboratory data was recorded through the medical chart review. Cardiovascular (CV) risk factors of interest were arterial hypertension, active smoking, hyperlipidemia, diabetes mellitus, and chronic kidney disease. Time to thrombosis was measured as the time from diagnosis until the first thrombotic (arterial or venous) event with patients being censored at the time of last follow-up or death, whereas time to bleeding was measured as the time from diagnosis until the first bleeding event. Categorical variables were compared with the chi-square test and continuous variables were analyzed with the Mann-Whitney U test. Survival curves were plotted using the Kaplan-Meier method. Statistics were performed with MedCalc Statistical Software®. Results: A total of 94 low-dose aspirin-treated patients (ET=36, PV=58) were included; median age was 69.5 years (range 21-92), 54 (57.4%) were females, 77 (81.9%) were JAK2 positive, 5 (5.3%) CALR-positive, and 75 (79.8%) received cytoreductive treatment. Nineteen (20.2%) patients were continuously treated with PPIs, mostly due to peptic ulcer disease (n=17, 89.5%), with pantoprazole (n=15, 78.9%) being the most frequent PPI. Male sex (p=0.011) and prior thrombosis (p=0.004) were associated with PPI use, whereas no correlations were found with respect to disease phenotype, age, palpable splenomegaly, mutational status, presence of constitutional symptoms, individual CV risk factors, cytoreductive treatment or blood cell counts (p>0.050 for all analyses). The median follow-up time was 55.5 months; 19 (20.2%) thrombotic (predominantly arterial, n=14/19, 73.6%) and 13 (13.8%) bleeding events (major GI bleedings=8, epistaxis=3, hemoptoa=1, prolonged bleeding after tooth extraction=1) occurred during this time. The use of PPIs was not associated with an increased risk of thrombosis (Figure 1A, p=0.158) or overall bleedings (p=0.229) and none of the patients treated with PPIs experienced GI bleeding events (Figure 1B, p=0.278). Summary/Conclusion: Considering that Helicobacter pylori infection and peptic ulcer disease are frequent in ET and PV patients, our results may provide some reassurance to physicians regarding the safety and efficacy of prolonged PPI use in patients treated with low-dose aspirin. These observations may be even more important in the light of recent evidence suggesting suboptimal platelet inhibition in ET with once-daily low-dose aspirin when compared to more intensive aspirin regimens which may also cause more abdominal discomfort. Limitations of this study are its retrospective design, limited number of patients included, and the lack of pharmacodynamic and pharmacokinetic assessments.Keywords: Thromboembolic events, Bleeding, Platelet, Myeloproliferative disorder" @default.
• W4385655443 created "2023-08-09" @default.
• W4385655443 creator A5015207045 @default.
• W4385655443 creator A5021087159 @default.
• W4385655443 creator A5049940470 @default.
• W4385655443 creator A5055539320 @default.
• W4385655443 creator A5063461221 @default.
• W4385655443 creator A5078947304 @default.
• W4385655443 creator A5085755441 @default.
• W4385655443 date "2023-08-01" @default.
• W4385655443 modified "2023-09-27" @default.
• W4385655443 title "PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN" @default.
• W4385655443 doi "https://doi.org/10.1097/01.hs9.0000975504.82530.25" @default.
• W4385655443 hasPublicationYear "2023" @default.
• W4385655443 type Work @default.
• W4385655443 citedByCount "0" @default.
• W4385655443 crossrefType "journal-article" @default.
• W4385655443 hasAuthorship W4385655443A5015207045 @default.
• W4385655443 hasAuthorship W4385655443A5021087159 @default.
• W4385655443 hasAuthorship W4385655443A5049940470 @default.
• W4385655443 hasAuthorship W4385655443A5055539320 @default.
• W4385655443 hasAuthorship W4385655443A5063461221 @default.
• W4385655443 hasAuthorship W4385655443A5078947304 @default.
• W4385655443 hasAuthorship W4385655443A5085755441 @default.
• W4385655443 hasBestOaLocation W43856554431 @default.
• W4385655443 hasConcept C126322002 @default.
• W4385655443 hasConcept C141071460 @default.
• W4385655443 hasConcept C2777628954 @default.
• W4385655443 hasConcept C2777849778 @default.
• W4385655443 hasConcept C2778080469 @default.
• W4385655443 hasConcept C2778837598 @default.
• W4385655443 hasConcept C2781057849 @default.
• W4385655443 hasConcept C2908647359 @default.
• W4385655443 hasConcept C71924100 @default.
• W4385655443 hasConcept C90924648 @default.
• W4385655443 hasConcept C99454951 @default.
• W4385655443 hasConceptScore W4385655443C126322002 @default.
• W4385655443 hasConceptScore W4385655443C141071460 @default.
• W4385655443 hasConceptScore W4385655443C2777628954 @default.
• W4385655443 hasConceptScore W4385655443C2777849778 @default.
• W4385655443 hasConceptScore W4385655443C2778080469 @default.
• W4385655443 hasConceptScore W4385655443C2778837598 @default.
• W4385655443 hasConceptScore W4385655443C2781057849 @default.
• W4385655443 hasConceptScore W4385655443C2908647359 @default.
• W4385655443 hasConceptScore W4385655443C71924100 @default.
• W4385655443 hasConceptScore W4385655443C90924648 @default.
• W4385655443 hasConceptScore W4385655443C99454951 @default.
• W4385655443 hasIssue "S3" @default.
• W4385655443 hasLocation W43856554431 @default.
• W4385655443 hasLocation W43856554432 @default.
• W4385655443 hasOpenAccess W4385655443 @default.
• W4385655443 hasPrimaryLocation W43856554431 @default.
• W4385655443 hasRelatedWork W2005995810 @default.
• W4385655443 hasRelatedWork W2087477276 @default.
• W4385655443 hasRelatedWork W2211542532 @default.
• W4385655443 hasRelatedWork W2347977317 @default.
• W4385655443 hasRelatedWork W2348564597 @default.
• W4385655443 hasRelatedWork W2357746782 @default.
• W4385655443 hasRelatedWork W2404737841 @default.
• W4385655443 hasRelatedWork W2490143083 @default.
• W4385655443 hasRelatedWork W3032676769 @default.
• W4385655443 hasRelatedWork W3198971710 @default.
• W4385655443 hasVolume "7" @default.
• W4385655443 isParatext "false" @default.
• W4385655443 isRetracted "false" @default.
• W4385655443 workType "article" @default.